BACKGROUND: Multiple myeloma is a life-threatening disease and despite the introduction of stem cell transplantation and novel agents such as thalidomide, lenalidomide, and bortezomib most patients will relapse and develop chemoresistant disease. Therefore, alternative therapeutic modes for myeloma are needed and cancer-testis antigens such as MAGE-C1/CT7 and MAGE-A3 have been suggested to represent a class of tumor-specific proteins particularly suited for targeted immunotherapies. Surprisingly, the biological role of cancer-testis genes in myeloma remains poorly understood. DESIGN AND METHODS: We performed the first investigation of the function of two cancer-testis antigens most commonly expressed in myeloma, MAGE-C1/CT7 and MAGE-A3, using an RNA interference-based gene silencing model in myeloma cell lines. Functional assays were used to determine changes in proliferation, cell adhesion, chemosensitivity, colony formation, and apoptosis resulting from gene-specific silencing. RESULTS: We show that the investigated genes are not involved in regulating cell proliferation or adhesion; however, they play an important role in promoting the survival of myeloma cells. Accordingly, knock-down of MAGE-C1/CT7 and MAGE-A3 led to the induction of apoptosis in the malignant plasma cells and, importantly, both genes were also essential for the survival of clonogenic myeloma precursors. Finally, silencing of cancer-testis genes further improved the response of myeloma cells to conventional therapies. CONCLUSIONS: Cancer-testis antigens such as MAGE-C1/CT7 and MAGE-A3 play an important role in promoting the survival of myeloma cells and clonogenic precursors by reducing the rate of spontaneous and chemotherapy-induced apoptosis and might, therefore, represent attractive targets for novel myeloma-specific therapies.
BACKGROUND:Multiple myeloma is a life-threatening disease and despite the introduction of stem cell transplantation and novel agents such as thalidomide, lenalidomide, and bortezomib most patients will relapse and develop chemoresistant disease. Therefore, alternative therapeutic modes for myeloma are needed and cancer-testis antigens such as MAGE-C1/CT7 and MAGE-A3 have been suggested to represent a class of tumor-specific proteins particularly suited for targeted immunotherapies. Surprisingly, the biological role of cancer-testis genes in myeloma remains poorly understood. DESIGN AND METHODS: We performed the first investigation of the function of two cancer-testis antigens most commonly expressed in myeloma, MAGE-C1/CT7 and MAGE-A3, using an RNA interference-based gene silencing model in myeloma cell lines. Functional assays were used to determine changes in proliferation, cell adhesion, chemosensitivity, colony formation, and apoptosis resulting from gene-specific silencing. RESULTS: We show that the investigated genes are not involved in regulating cell proliferation or adhesion; however, they play an important role in promoting the survival of myeloma cells. Accordingly, knock-down of MAGE-C1/CT7 and MAGE-A3 led to the induction of apoptosis in the malignant plasma cells and, importantly, both genes were also essential for the survival of clonogenic myeloma precursors. Finally, silencing of cancer-testis genes further improved the response of myeloma cells to conventional therapies. CONCLUSIONS:Cancer-testis antigens such as MAGE-C1/CT7 and MAGE-A3 play an important role in promoting the survival of myeloma cells and clonogenic precursors by reducing the rate of spontaneous and chemotherapy-induced apoptosis and might, therefore, represent attractive targets for novel myeloma-specific therapies.
Authors: C Pellat-Deceunynck; M P Mellerin; N Labarrière; G Jego; A Moreau-Aubry; J L Harousseau; F Jotereau; R Bataille Journal: Eur J Immunol Date: 2000-03 Impact factor: 5.532
Authors: A O Güre; E Stockert; K C Arden; A D Boyer; C S Viars; M J Scanlan; L J Old; Y T Chen Journal: Int J Cancer Date: 2000-03-01 Impact factor: 7.396
Authors: John De Vos; Thomas Thykjaer; Karin Tarte; Matthias Ensslen; Pierre Raynaud; Guilhem Requirand; Florence Pellet; Véronique Pantesco; Thierry Rème; Michel Jourdan; Jean-François Rossi; Torben Ørntoft; Bernard Klein Journal: Oncogene Date: 2002-10-03 Impact factor: 9.867
Authors: M Tinguely; B Jenni; A Knights; B Lopes; D Korol; V Rousson; A Curioni Fontecedro; S B Cogliatti; A G Bittermann; U Schmid; C Dommann-Scherrer; R Maurer; C Renner; N M Probst-Hensch; H Moch; A Knuth; A Zippelius Journal: Cancer Sci Date: 2008-02-27 Impact factor: 6.716
Authors: Johannes A Veit; Daniela Heine; Julia Thierauf; Jochen Lennerz; Subasch Shetty; Patrick J Schuler; Theresa Whiteside; Dirk Beutner; Moritz Meyer; Inga Grünewald; Gerd Ritter; Sacha Gnjatic; Andrew G Sikora; Thomas K Hoffmann; Simon Laban Journal: Head Neck Date: 2016-02-13 Impact factor: 3.147
Authors: Tricia Nardiello; Achim A Jungbluth; Anna Mei; Maurizio Diliberto; Xiangao Huang; Ania Dabrowski; Valéria C C Andrade; Rebecca Wasserstrum; Scott Ely; Ruben Niesvizky; Roger Pearse; Morton Coleman; David S Jayabalan; Nina Bhardwaj; Lloyd J Old; Selina Chen-Kiang; Hearn Jay Cho Journal: Clin Cancer Res Date: 2011-05-12 Impact factor: 12.531
Authors: Neehar Bhatia; Tony Z Xiao; Kimberly A Rosenthal; Imtiaz A Siddiqui; Saravanan Thiyagarajan; Brendan Smart; Qiao Meng; Cindy L Zuleger; Hasan Mukhtar; Shannon C Kenney; Mark R Albertini; B Jack Longley Journal: J Invest Dermatol Date: 2012-10-25 Impact factor: 8.551
Authors: Otavia L Caballero; Qi Zhao; Donata Rimoldi; Brian J Stevenson; Suzanne Svobodová; Sylvie Devalle; Ute F Röhrig; Anna Pagotto; Olivier Michielin; Daniel Speiser; Jedd D Wolchok; Cailian Liu; Tanja Pejovic; Kunle Odunsi; Francis Brasseur; Benoit J Van den Eynde; Lloyd J Old; Xin Lu; Jonathan Cebon; Robert L Strausberg; Andrew J Simpson Journal: PLoS One Date: 2010-09-16 Impact factor: 3.240